Peak Bio, Inc. Price & Performance (PKBO)

Halozyme Therapeutics stock climbed nearly 5% after the company beat first-quarter earnings forecasts and raised its 2025 guidance. The announcement of a $250 million share repurchase program and positive analyst outlooks further fueled investor enthusiasm, highlighting strong fiscal management and confidence in future growth.12

Kodiak Sciences reported a net loss of $57.5 million for Q1 2025 but emphasized advancements in its retina-focused biotech pipeline. The company maintains sufficient cash to fund operations into 2026 and plans an R&D update in July, with several Phase 3 trial milestones anticipated in the coming year.34

AmplifyBio announced it will cease operations after unsuccessful attempts to secure investment or a buyer. The company cited a challenging funding environment for early-phase biotech as the main reason, reflecting broader market difficulties impacting growth and sustainability in the sector.56